134 related articles for article (PubMed ID: 38918837)
1. Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.
Chen J; Cao D
World J Surg Oncol; 2024 Jun; 22(1):169. PubMed ID: 38918837
[TBL] [Abstract][Full Text] [Related]
2. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
3. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
4. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Kim NK; Choi CH; Seong SJ; Lee JM; Lee B; Kim K
Gynecol Oncol; 2024 Apr; 183():68-73. PubMed ID: 38520881
[TBL] [Abstract][Full Text] [Related]
7. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
8. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
[TBL] [Abstract][Full Text] [Related]
9. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
[TBL] [Abstract][Full Text] [Related]
12. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
Lv X; Guo L; Wang C
J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
[TBL] [Abstract][Full Text] [Related]
14. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
16. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
[No Abstract] [Full Text] [Related]
18. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
Pronin SM; Novikova OV; Andreeva JY; Novikova EG
Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
[TBL] [Abstract][Full Text] [Related]
20. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]